About Naurex

Naurex is a biopharmaceutical company developing transformative therapies for challenging diseases of the central nervous system. All of our programs, including two rapid-acting antidepressants currently in clinical development, stem from our proprietary platform for discovering novel compounds that work through a new mechanism, modulating the NMDA receptor to enhance pathways involved with neuroplasticity.

Learn more about Naurex »

Our Programs

Naurex has two therapies currently in clinical development. Rapastinel (GLYX-13) has completed Phase 2 clinical studies as an adjunctive therapy in major depressive disorder and has shown rapid-acting, robust, and sustained antidepressant activity in patients unable to achieve an adequate response to other anti-depressants. Rapastinel (GLYX-13) has been well-tolerated, with none of the pyschotomimetic side effects associated with other drugs and mechanisms that target the NMDA receptor. NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder. We are also advancing additional molecules from our proprietary drug discovery platform into clinical development for the treatment of other challenging CNS diseases.

Learn more about our programs »

Copyright © 2015. Naurex Inc. All rights reserved.